stoxline Quote Chart Rank Option Currency Glossary
  
Beyond Air, Inc. (XAIR)
0.4739  -0.035 (-6.86%)    11-08 16:00
Open: 0.5088
High: 0.51
Volume: 274,121
  
Pre. Close: 0.5088
Low: 0.4632
Market Cap: 34(M)
Technical analysis
2024-11-08 4:50:22 PM
Short term     
Mid term     
Targets 6-month :  0.68 1-year :  0.8
Resists First :  0.58 Second :  0.68
Pivot price 0.45
Supports First :  0.41 Second :  0.3
MAs MA(5) :  0.47 MA(20) :  0.42
MA(100) :  0.48 MA(250) :  1.12
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  62.2 D(3) :  58.9
RSI RSI(14): 55.1
52-week High :  2.35 Low :  0.29
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XAIR ] has closed below upper band by 40.7%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.51 - 0.51 0.51 - 0.52
Low: 0.46 - 0.46 0.46 - 0.46
Close: 0.47 - 0.47 0.47 - 0.48
Company Description

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Headline News

Tue, 29 Oct 2024
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast - The Manila Times

Wed, 02 Oct 2024
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks - StockTitan

Mon, 30 Sep 2024
Beyond Air's SWOT analysis: FDA-approved NO generator faces cash burn challenges - Investing.com

Fri, 27 Sep 2024
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times

Fri, 27 Sep 2024
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed - StockTitan

Fri, 27 Sep 2024
Beyond Air Back to Earth on Purchase Agreement - Baystreet.ca

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out -29 (M)
Shares Float 0 (M)
Held by Insiders 7.219e+007 (%)
Held by Institutions 1.7e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.64
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 988.4 %
Return on Equity (ttm) -63.5 %
Qtrly Rev. Growth 1.78e+006 %
Gross Profit (p.s.) 0
Sales Per Share -18579
EBITDA (p.s.) 0
Qtrly Earnings Growth -5.836e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.29
Price to Sales -0.01
Price to Cash Flow 0
Stock Dividends
Dividend 1.35e+006
Forward Dividend 444130
Dividend Yield 284870000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android